• MustGrow posted net profit from continuing operations of $0.4 million in Q2 2026, swinging from a $0.9 million loss a year earlier.
• Licensing revenue of $1.4 million was recognized in the quarter, while expenses from continuing operations held at $0.9 million.
• TerraSante sales revenue fell to $75,000 from $313,000 in Q2 2025; gross margin was nil due to costly air freight.
• Cash and equivalents totaled $4.4 million at June 30, 2026, with working capital of $5.2 million.
• Management cited contract manufacturers commissioning new equipment; year-to-date TerraSante sales were $0.9 million as of Aug. 15.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MustGrow Biologics Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608271701NEWSFILECNPR____20260827_311893_1) on August 27, 2026, and is solely responsible for the information contained therein.